Jane Street
RLMD icon

Jane Street’s Relmada Therapeutics RLMD Stock Holding History

Jane Street’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-102,200
Closed -$3.78M – 9989
2022
Q3 		$3.78M Buy
+102,200
New +$2.83M ﹤0.01% 3068
2021
Q3 		– Sell
-21,900
Closed -$701K – 10596
2021
Q2 		$701K Buy
+21,900
New +$761K ﹤0.01% 6588

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street's RLMD Position: Q2 2026 in Review

Jane Street sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 221,969 shares — an estimated $1.54M sold.

Jane Street first reported a position in RLMD in Q1 2020 and held it in 14 quarters. The position peaked at $1.54M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Jane Street reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 221,969 Relmada Therapeutics shares in Q2 2026, an estimated $1.54M.
  • Jane Street first reported a position in Relmada Therapeutics in Q1 2020 and held it in 14 quarters.
  • Jane Street's Relmada Therapeutics position peaked at $1.54M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.